Granisetron
- Generic Name
- Granisetron
- Brand Names
- Sancuso, Sustol
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24N4O
- CAS Number
- 109889-09-0
- Unique Ingredient Identifier
- WZG3J2MCOL
Overview
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Background
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Indication
For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
Associated Conditions
- Nausea and vomiting
Clinical Trials
FDA Approved Products
Granisetron Hydrochloride
Manufacturer:Mylan Institutional LLC
Route:INTRAVENOUS
Strength:0.1 mg in 1 mL
Approved: 2017/08/31
NDC:67457-861
Granisetron Hydrochloride
Manufacturer:Mylan Institutional LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2017/08/31
NDC:67457-864
Granisetron
Manufacturer:Fresenius Kabi USA, LLC
Route:INTRAVENOUS
Strength:1 mg in 1 mL
Approved: 2022/07/31
NDC:63323-319
SUSTOL
Manufacturer:Heron Therapeutics, Inc.
Route:SUBCUTANEOUS
Strength:10 mg in 0.4 mL
Approved: 2017/05/31
NDC:47426-101
Sancuso
Manufacturer:Physicians Total Care, Inc.
Route:TRANSDERMAL
Strength:3.1 mg in 24 h
Approved: 2011/11/01
NDC:54868-5985
Singapore Approved Products
KYTRIL FOR INFUSION 3 mg/3ml
Manufacturer:CENEXI SAS
Form:INJECTION
Strength:3 mg/3 ml
Online:Yes
Approved: 1992/06/22
Approval:SIN07089P
EMENAT TABLETS 1 MG
Manufacturer:Natco Pharma Limited-Pharma Division
Form:TABLET
Strength:1.0 mg
Online:Yes
Approved: 2017/02/09
Approval:SIN15174P
Granisetron Kabi concentrate for solution for infusion 1mg/ml
Manufacturer:LABESFAL – Laboratórios Almiro S.A. (Fresenius Kabi Group)
Form:INFUSION, SOLUTION CONCENTRATE
Strength:1mg/ml
Online:Yes
Approved: 2013/09/23
Approval:SIN14409P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath